Pharmacist Medication Insights: for Panzyga for Primary Humoral Immunodeficiency

July 5, 2021

Panzyga is indicated for the treatment of primary humoral immunodeficiency, chronic inflammatory demyelinating polyneuropathy, and chronic immune thrombocytopenia.

Panzyga (immune globulin intravenous [Human]-ifas) is indicated for the following:

For the treatment of adults 18 years of age and older with chronic inflammatory demyelinating polyneuropathy (CIDP) to improve neuromuscular disability and impairment.
Primary humoral immunodeficiency (PI) in patients 2 years of age and older.
Chronic immune thrombocytopenia (ITP) in adults.